Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195

Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

Eric L. Sievers, Richard A. Larson, Edward A. Stadtmauer et al. · Journal of Clinical Oncology · 2001 · 882 citations

Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.

A.J. Grillo-López, Christine A. White, C. Varns et al. · PubMed · 1999 · 294 citations

Clinical significance of cytogenetics in acute myeloid leukemia.

Krzysztof Mrózek, Kati Heinonen, Albert de la Chapelle et al. · PubMed · 1997 · 263 citations

A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide.

David A. Scheinberg, Dennis Lovett, Chaitanya Divgi et al. · Journal of Clinical Oncology · 1991 · 227 citations

Mixed-phenotype Acute Leukemia, Immunology, Immunotherapy +20

A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity

P C Caron, JG Jurcic, R.D. Finn et al. · Blood · 1994 · 179 citations · Full text